News in brief

March 2009
Nature Medicine;Mar2009, Vol. 15 Issue 3, p228
Academic Journal
The article offers news briefs related to law and policy in medicine. The biotech company Geron Corp. announced on January 23, 2009 that it received approval from the Food and Drug Administration (FDA) to test a therapy based on human embryonic stem cells. On February 6, 2009, FDA approved the first drug antithrombin produced by transgenic livestock. President Barack Obama signed an economic recovery bill to support biomedical research and improve facilities over the next two years.


Related Articles

  • Geron gets green light for human trial of ES cell–derived product. Alper, Joe // Nature Biotechnology;Mar2009, Vol. 27 Issue 3, p213 

    The article states that the U.S. Food and Drug Administration (FDA) has approved the first human trials of embryonic stem (hES) cells. This decision came on the eve of President Barack Obama's anticipated policy change concerning such research, and it will allow the pharmaceutical company Geron...

  • Next Leg in hESC Race. Agres, Ted // Drug Discovery & Development;Mar2009, Vol. 12 Issue 3, p6 

    The article reports on the approval of a clinical trial, which involves a human embryonic stem cell (hESC)-based therapy, by the U.S. Food and Drug Administration (FDA). According to the article, the approval is depicted to be a triumph of science over politics and acclaims a much-needed...

  • Geron Soars as First ESC Trial Clears FDA Hurdle. Boggs, Jennifer // BioWorld Today;1/26/2009, Vol. 20 Issue 15, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Phase I trial of GRNOPCI, human embryonic stem cells (hESC)-derived oligodendrocytes of Geron Corp. in patients with spinal cord injury. Thomas Okarma, president and chief executive officer of Geron,...

  • Geron Slips on Latest Delay to ESC Trial in Spinal Cord Injury. Boggs, Jennifer // BioWorld Today;8/19/2009, Vol. 20 Issue 159, p1 

    The article reports on the delay in the clinical trial of the human embryonic stem cell-based therapy GRNOPC1 developed by Menlo Park, California-based Geron Corp. It relates that the delay is pending U.S. Food and Drug Administration (FDA) review of recently submitted animal data. It presents...

  • FDA approves stem cell clinical trial. Collier, Roger // CMAJ: Canadian Medical Association Journal;9/7/2010, Vol. 182 Issue 12, pE584 

    The article reports that the U.S. Food and Drug Administration (FDA) have authorized the biopharmaceutical company Geron Corp. to conduct the first U.S. clinical trials on human embryonic stem cells.

  • Stem Cell Diversification. Hobson, Katherine // U.S. News & World Report;Aug2009, Vol. 146 Issue 7, p31 

    The article examines the decision of U.S. President Barack Obama to remove government policy that had restricted the use of embryonic stem cells in medical applications. While much progress has been made in the research of adult stem cells, embryonic cells still hold the most promise for...

  • Animal Spine Cysts Delay Trial with Geron's ESC for Injuries. Boggs, Jennifer // BioWorld Today;8/28/2009, Vol. 20 Issue 166, p1 

    The article reports that trial of the human embryonic stem cell (hESC)-based therapy GRNOPCI has been delayed by Geron Corp. because of the lack of cysts in animal models. The company has yet to decide when to start the first phase of the trial with the hESC-derived oligodendrocyte therapy. On...

  • Stem cells ready for prime time. Wadman, Meredith // Nature;1/29/2009, Vol. 457 Issue 7229, p516 

    The article discusses the approval by the U.S. Food and Drug Administration (FDA) for clinical trials of human embryonic stem-cell treatment for the spinal-cord injuries. Topics include an overview of the biotechnology company Geron, who will be conducting the study, how it’s affected the...

  • US stem cell climate improves, raising concerns elsewhere. Siva, Nayanah // Nature Medicine;Mar2009, Vol. 15 Issue 3, p224 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the biotech company Geron Corp. to perform a stem cell trial for people with acute spinal injury. It states that the trial is designed to determine the safety of the stem cell approach to 8-10 paralyzed subjects....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics